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Abstract
Background: Ubiquitin speciﬁc peptidase 14 (USP14), a deubiquitinating
enzyme, has been documented as a key element to regulate the proteolysis func-
tion of proteasomes and an attractive therapeutic target for several cancers.
Herein, we elucidate the role of USP14 in predicting the prognosis of patients
with esophageal squamous cell carcinoma (ESCC).
Methods: USP14 expression was detected in ESCC tissues and matched adjacent
non-tumorous tissues by quantitative real-time reverse transcription-PCR and
immunohistochemistry. Kaplan–Meier survival analysis was used to assess the
correlation between USP14 expression and prognosis in ESCC patients. Univari-
ate and multivariate analysis was conducted with a Cox proportional hazards
model to determine whether USP14 is an independent prognostic factor.
Result: Overexpression of USP14 was observed in approximately 60% of tested
ESCC samples compared to their paired non-tumor esophageal tissues at both
RNA and protein levels, and was signiﬁcantly associated with distant metastasis
(P = 0.001). Kaplan–Meier analysis showed that USP14 overexpression was
related to poorer overall patient survival. Univariate and multivariate analyses
demonstrated that USP14 was an independent risk factor for overall survival.
Conclusion: The ﬁndings in this study suggest that USP14 could be used as a
potential prognostic marker for ESCC patients.
Introduction
Esophageal cancer caused an estimated 400 200 deaths in
2012 worldwide, which makes it the sixth and the ninth
leading cause of cancer death in men and women respec-
tively.1 Esophageal squamous cell carcinoma (ESCC), the
most common histological type of esophageal cancer, is a
threatening malignancy with aggressive biological behavior
and a poor prognosis. In addition to unhealthy eating and
lifestyle habits,2 hereditary variability and molecular regula-
tion have been found to be increasingly vital in the initia-
tion and development of ESCC. Accordingly, clinical
investigators are screening to locate potential biological
molecules to predict ESCC prognosis.
Recently, we performed integrative RNA sequencing
(RNA-Seq) to identify differentially expressed genes
between three pairs of clinical samples of ESCC and their
adjacent non-tumor tissues. Overexpression of ubiquitin
speciﬁc peptidase 14 (USP14) was observed in all three
ESCC tumor tissues compared to their matched non-tumor
counterparts. USP14 belongs to the ubiquitin-speciﬁc pro-
tease (USP) family, which cleave the ubiquitin moiety from
ubiquitin-fused precursors. USP14 was ﬁrst associated with
neurological disease, such as skeletal muscle atrophy, syn-
aptic activity, and long-term memory formation.3–5 Recent
research has revealed that USP14 expression is related to
liver and lymph node metastases in colorectal cancer,6
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advanced stage of hepatocellular carcinoma,7 and poor
prognosis in epithelial ovarian cancer patients.8 Overex-
pression of USP14 could increase tumor cell growth in
lung adenocarcinoma.9 Conversely, knockdown of USP14
inhibited cell proliferation of epithelial ovarian cancer,
multiple myeloma, Waldenström macroglobulinemia, and
acute myeloid leukemia.8,10–12 USP14 is a tempting target
for designing clinical drugs; however, its role in ESCC
remains unknown.
Herein we detected USP14 expression in ESCC tissues
and paired non-tumor specimens and explored its clinico-
pathological features and prognostic value in ESCC.
Methods
Patients and tissue samples
Forty six primary ESCC specimens and their non-tumor
counterparts were obtained from Linzhou People’s Hospi-
tal, Henan, China. Queen Mary Hospital, Hong Kong,
China kindly donated a set of tissue microarray containing
132 ESCC samples. None of the patients in the sample had
received any preoperative treatments. Permission was
obtained from all patients prior to their inclusion in the
study. The Medical Ethics Committee of Sun Yat-sen Uni-
versity Cancer Center, Zhenzhou University and Hong
Kong University granted ethical approval for this study.
Six ESCC cell lines (KYSE30, KYSE140, KYSE180,
KYSE410, KYSE510, and KYSE520) were obtained from
DSMZ (Braunschweig, Germany), the German Resource
Centre for Biological Material.13 Four Chinese ESCC cell
lines (EC18, EC109, EC9706, and HKESC1) were kindly
donated by Professor Tsao and Professor Srivastava (The
University of Hong Kong).14
Quantitative real-time reverse
transcription-PCR
Total RNA was extracted from clinical samples using Trizol
reagent (Invitrogen, Carlsbad, CA, USA) and was reverse-
transcribed using a PrimeScriptRT reagent Kit (Promega,
Madison, WI, USA) according to the manufacturer’s
instruction. Quantitative real-time reverse transcription
(RT)-PCR was then performed using SYBR Green Super-
Mix (Roche, Basel, Switzerland) and ABI7900HT Fast Real
Time PCR system (Applied Biosystems, Foster City, CA,
USA). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as internal control. The primers used
are as follows: GAPDH (50-CCATGTTCGTCATGGG-
TGTGAACCA-30 and 50-GCCAGTAGAGGCAGGGAT
GATGTTG-30) and USP14 (50-GAGT-TGGACCTTT-
CCAGA-30 and 50-TGCTTGCACAG-ATGTGA-30). The
value of relative expression for each sample was averaged
and compared using the Ct method. ΔΔCt(sample) = ΔCt
(sample) − ΔCt(calibrator), ΔCt(sample) = Ct(sample) of
USP14 − Ct(sample) of GAPDH; ΔCt(calibrator) = Ct(cali-
brator) of USP14 − Ct(calibrator) of GAPDH. The calibra-
tor was deﬁned as the pooled samples from 46 adjacent
non-tumorous tissues.
Western blot analysis
Equal amounts of protein were separated by 12% dodecyl
sulfate, sodium salt (SDS)-polyacrylamide gel electrophore-
sis (PAGE) and transferred to microporous polyvinylidene
diﬂuoride (PVDF) Western blotting membranes (Roche,
Basel, Switzerland). Membranes were incubated with anti-
body against USP14 (1:1000; Proteintech, Chicago, IL,
USA) or β-actin (1:2000; Abgent, San Diego, CA, USA).
Blots were developed using a Luminata Crescendo Western
HRP Substrate (Millipore, Billerica, MA, USA). β-actin was
used as a loading control.
Immunohistochemical staining
Immunohistochemical staining was conducted, as previ-
ously described.15 Anti-USP14 antibody (1:100; Protein-
tech) was applied as a ﬁrst antibody. Immunoreactivity was
visualized using an Envision detection system (DAKO,
Carpinteria, CA, USA), and the nuclei were counterstained
with hematoxylin. An immunoreactivity score (IRS) system
was applied, as previously described.16 The percentage of
USP14-positive cells was scored as: 0, <5%; 1, 5–25%;
2, 25–50%; 3, 50–75%; and 4, 75–100%. The intensity of
USP14-positive staining was scored as 0, negative; 1, weak;
2, moderate; and 3, strong. The total score was determined
using the following formula: Staining index = intensity ×
positive percentage. According to receiver operating char-
acteristic (ROC) curve analyses, the optimum cut-off value
for USP14 was 6; therefore, a staining index ≤6 was con-
sidered low expression, and a staining index >6 was con-
sidered high expression.
Statistical analysis
All statistical analyses were performed using SPSS version
16.0 (SPSS Inc., Chicago, IL, USA). An ROC curve was
generated to determine the cut-off value for USP14 expres-
sion that yielded the highest combined sensitivity and
speciﬁcity with respect to distinguishing overall 10-year
survivors from non-survivors. A paired two-tailed t-test
was used to compare the level of USP14 messenger (m)
RNA in primary ESCC samples and their paired adjacent
non-tumorous tissues. The relationship between USP14
expression and clinicopathologic characteristics was meas-
ured by χ2 or Fisher’s exact tests. Overall survival was
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calculated from the date of surgery to the date of death
from ESCC or the last follow up. Kaplan–Meier analysis
with log-rank test was employed to calculate the prognostic
value. Univariate and multivariate survival analyses were
performed using the Cox proportional hazard model with
a forward stepwise procedure (the entry and removal prob-
abilities were 0.05 and 0.10, respectively). Statistical signiﬁ-
cance was considered when P < 0.05.
Results
Ubiquitin speciﬁc peptidase 14 (USP14)
expression is notably upregulated in
esophageal squamous cell
carcinoma (ESCC)
Our prior RNA-seq proﬁling data showed that USP14 was
upregulated in all three tested ESCC tumor tissues. Quanti-
tative real-time RT-PCR was applied to measure the USP14
expression level in 46 pairs of ESCC and paired adjacent
non-tumor tissues. Overexpression of USP14 was observed
in 30/46 (65.2%) ESCC samples (deﬁned as >twofold
increase) compared to non-tumor counterparts. The aver-
age level of USP14 expression was remarkably higher in
ESCC tumor tissues than in their non-tumor counterparts
(3.74 vs. 1.44; P < 0.001, paired Student’s t test) (Fig 1a).
To conﬁrm our ﬁndings, we subsequently examined the
USP14 protein level in 10 pairs of ESCC and adjacent non-
tumor tissues. Western blotting showed that USP14 was
upregulated in six out of 10 ESCC tissues (Fig 1b). The
mRNA and protein expression of USP14 in 10 ESCC cell
lines and one immortalized esophageal epithelial cell line
(NE1) was then detected. High USP14 expression was
detected in all ESCC cell lines but not in NE1 (Fig 1c).
Correlation of USP14 expression with
clinicopathological variables
The ESCC tissue microarray containing 132 pairs of ESCC
specimens was analyzed for USP14 expression by immuno-
histochemistry. Informative immunohistochemical results
were obtained from 125 pairs of ESCCs. USP14 localized at
the cytoplasm and nucleus of ESCC cells and exhibited dif-
ferent staining intensities (Fig 2a). Enhanced USP14
expression was detected in 68/125 (54.4%) informative
ESCC tissues compared to their adjacent non-tumor tis-
sues. To further evaluate the potential utility of USP14
expression as a diagnostic marker for ESCC, ROC curve
Figure 1 Upregulation of ubiquitin
speciﬁc peptidase (USP)14 in esopha-
geal squamous cell carcinoma (ESCC).
(a) USP14 messenger RNA expression
(dot plots) in ESCC and matched adja-
cent non-tumor specimens from
46 cases. β-actin was used as an
endogenous control. P < 0.001, paired
t-test. (b) Western blotting exhibited
that USP14 was upregulated in six out
of 10 pairs of ESCC tissues. (c) USP14
messenger RNA (left) and protein
expression (right) in 10 ESCC cell lines
and one immortalized esophageal epi-
thelial cell line (NE1). β-actin was used
as an endogenous control.
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analysis was performed and the optimal cut-off value of
USP14 expression with the best discriminatory power was
determined to be 6. Therefore, 125 informative ESCC cases
were divided into two groups: high (index > 6, n = 58) and
low (index ≤ 6, n = 67) expression. The association
between USP14 expression and clinicopathological features
was statistically analyzed and is summarized in Table 1.
High USP14 expression was signiﬁcantly associated with
distant metastasis (P = 0.001). No correlation was observed
between USP14 expression and other clinicopathological
indexes.
Overexpression of USP14 is associated
with poor prognosis
Kaplan–Meier analysis indicated that high USP14 expres-
sion was signiﬁcantly associated with poorer overall sur-
vival (OS) (log-rank test, P < 0.001) (Fig 2b, left). The
three, ﬁve, and eight-year OS rate in the high USP14
expression group was 13.4, 5.8, and 2.0%, respectively,
compared to 57.5, 37.7, and 25.4%, respectively, in the low
USP14 expression group (log-rank test, P < 0.001). In uni-
variate analysis, the statistically signiﬁcant predictors for a
patient’s OS were gender (P = 0.013), age (P = 0.004),
tumor invasion (P = 0.004), lymph node metastasis
(P = 0.015), and USP14 expression (P < 0.001) (Table 2).
Multivariate Cox regression analysis showed that age ≥60
(P = 0.002) and USP14 overexpression (P < 0.001) are
independent prognostic factors for poor survival in
patients with ESCC (Table 2). Further, in a stratiﬁed sur-
vival analysis according to the clinical stage, USP14 expres-
sion could differentiate the prognosis of patients at clinical
tumor node metastasis (TNM) stages I–II (P < 0.001)
(Fig 2b, middle) and III–IV (P = 0.004) (Fig 2b, right).
Discussion
In a living mammalian cell, the ubiquitin–proteasome sys-
tem (UPS) and deubiquitinases (DUBs) control the stabil-
ity of around 90% of protein, including cell cycle
regulating proteins such as cyclins, cyclin-dependent
kinases, and their inhibitors.17 DUBs have been implicated
as important regulators of oncogenes and tumor suppres-
sors as they promote destabilization by targeting them for
degradation or regulating their activity (activation or
inactivation).18 The DUB superfamily consists of ﬁve
subfamilies: USPs, otubain-domain containing proteins,
Machado-Joseph Domain (Josephin domain)-containing
proteins, and ubiquitin C-terminal hydrolases.18 USP14 has
gained increasing attention because of its high expression
and important function in many types of tumors. We
found that ESCC patients with high USP14 expression
have poorer survival compared to those with low USP14
expression. Furthermore, multivariate Cox regression
Figure 2 High expression of ubiquitin speciﬁc peptidase (USP)14 in esophageal squamous cell carcinoma (ESCC) tumor tissues was associated with
poor prognosis in ESCC patients. (a) Representative images of USP14 immunohistochemistry staining in ESCC and normal esophageal tissues (origi-
nal magniﬁcation, 200×; scale bar, 100 μm). (b) Kaplan–Meier analysis of overall survival for USP14 expression in: all 125 cases (left), ESCC patients
with clinical tumor node metastasis (TNM) stage I–II (middle), and clinical stage III–IV (right).
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analysis showed that USP14 overexpression was an inde-
pendent prognostic factor in ESCC patients.
Previous studies have shown that elevated USP14
expression is related to liver and lymph node metastases in
colorectal cancer, advanced stage of hepatocellular carci-
noma, and intrahepatic cholangiocarcinoma cell differenti-
ation.6,7,19 Consistent with these ﬁndings, we found that
high USP14 expression was remarkably related to distant
metastasis in ESCC. A recent study revealed that USP14
knockdown inhibited the migration of breast cancer cells
by increasing the expression of vimentin and reducing the
expression of E-cadherin, suggesting that USP14 might
enhance the metastatic ability of breast cancer cells by
initiating the epithelial-mesenchymal transition process.20
However, whether USP14 promotes ESCC metastasis
through the same mechanism or other pathways remains
unclear.
Ubiquitin speciﬁc peptidase 14 has been proven to
inhibit the proteasome in vitro.21 Ubiquitinated tau is a
substrate protein for proteasomal degradation.22 Expressing
wild-type USP14 in Usp14−/− murine embryonic ﬁbroblasts
could increase tau expression levels, indicating that USP14
suppressed the ability of the proteasome to degrade tau.23
The deubiquitinating activity of the 19S regulatory particle
has recently been proven to be a promising target for can-
cer treatment. b-AP15, a small molecule inhibitor of two
19S regulatory-particle-associated deubiquitinases, USP14
and ubiquitin C-terminal hydrolase 5, could efﬁciently
induce cell apoptosis or cell death in colorectal cancer cell
line HCT116.24 In addition, b-AP15 can suppress the
growth of FaDu squamous cell carcinoma cells.25 Our stra-
tiﬁed survival analysis indicated that high USP14 expres-
sion could distinguish poor outcomes of patients with
either early (TNM stage I–II) or advanced clinical stage
(TNM stage III–IV), suggesting that USP14 may play a sig-
niﬁcant role throughout the development of ESCC. There-
fore, inhibitors targeting USP14, such as b-AP15, may be
speciﬁcally effective for ESCC patients with high USP14
expression.
In this study, elevated USP14 expression was detected at
both mRNA and protein levels. It has been reported that
USP14 expression could be regulated at mRNA level. In
non-small cell lung cancer, miR-4782-3p was reported to
bind the 30 untranslated region region of USP14 mRNA
and inhibited its expression.26 The expression status of
miR-4782-3p in ESCC and its inﬂuence on USP14 expres-
sion remain unknown. Xu et al. reported that serine/threo-
nine kinase could phosphorylate USP14 at Ser432, thus
activating its deubiquitinating activity by transforming its
catalytic site from the inactive conformation to the active
Table 1 Association of USP14 expression with clinicopathological fea-
tures in ESCC
Clinical features Cases
USP14 protein expression
P
value
Low
level (%)
High
level (%)
Age (years) 1.000
≤59 50 27 (54.0%) 23 (46.0%)
>59 75 40 (53.3%) 35 (46.7%)
Gender 0.076
Male 89 43 (48.3%) 46 (51.7%)
Female 36 24 (66.7%) 12 (33.3%)
Differentiation 0.149
Grade 1 18 6 (33.3%) 12 (66.7%)
Grade 2 73 43 (58.9%) 30 (41.1%)
Grade 3 34 19 (52.9%) 16 (47.1%)
Tumor invasion 0.463
T1–2 48 28 (58.3%) 20 (41.7%)
T3–4 77 39 (50.6%) 38 (49.4%)
Lymph node
metastasis
0.213
No 66 39 (59.1%) 27 (40.9%)
Yes 59 28 (47.5%) 31 (52.5%)
Distant metastasis 0.001
No 81 52 (62.4%) 29 (35.8%)
Yes 44 15 (34.1%) 29 (65.9%)
TNM stage 0.205
I–II 71 42 (59.2%) 29 (40.8%)
III–IV 54 25 (46.3%) 29 (53.7%)
Statistical signiﬁcance (P < 0.05) is shown in bold. ESCC, esophageal
squamous cell carcinoma; TNM, tumor node metastasis; USP, ubiquitin
speciﬁc peptidase.
Table 2 Cox proportional hazard regression analyses for overall survival
Clinical features
Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Age 1.906 (1.234–2.946) 0.004 2.074 (1.319–3.262) 0.002
Gender 0.537 (0.330–0.875) 0.013 0.858 (0.506–1.455) 0.570
Differentiation 0.801 (0.552–1.163) 0.244 - -
Tumor invasion 1.982 (1.245–3.155) 0.004 1.244 (0.782–2.310) 0.285
Lymph node metastasis 1.701 (1.110–2.605) 0.015 1.158 (0.708–1.893) 0.559
Distant metastasis 1.380 (0.913–2.085) 0.126 - -
USP14 expression 2.953 (1.930–4.518) < 0.001 2.499 (1.607–3.886) < 0.001
Statistical signiﬁcance (P < 0.05) is shown in bold. CI, conﬁdence interval; HR, hazard ratio; USP, ubiquitin speciﬁc peptidase.
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form.27 Whether the activity of USP14 is regulated by ser-
ine/threonine kinase in ESCC is still questionable.
In conclusion, USP14 may serve as a valuable marker
for prognosis in ESCC.
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